An analyst challenges the common view that Constellium is highly cyclical and overly dependent on aluminum prices. The article explains that Constellium's earnings drivers are more complex and not solely linked to commodity price swings, suggesting a more stable earnings profile. This insight encourages investors to reconsider the company's risk profile and valuation, highlighting potential undervaluation due to misunderstood business dynamics. The analyst has a long position in Constellium and emphasizes fundamental analysis to uncover such opportunities.
Coda Octopus Group reported Q3 earnings per share of $0.12 and revenue of $7.7 million, exceeding analyst expectations. The company's growth was driven by its defense engineering and acoustic businesses, which offset a decline in marine technology sa...
Baldwin Group is going private in a $7.7 billion all-cash deal led by Sequence Holdings and DFO Management, offering shareholders $32.50 per share, an 88% premium over the June 2026 price. The transaction will delist Baldwin from Nasdaq and is expect...
BTIG increased its price target for Cullinan Therapeutics to $40, reflecting a potential 93% upside from the current stock price of around $20.73. This upgrade follows successful Phase 3 trial results for zipalertinib, a treatment for non-small cell ...
Pacifica Silver Corp. held its annual general meeting where all resolutions were approved, including the re-election of directors and appointment of auditors. Following the meeting, Alan Tam resigned as CFO and director, with Israel Munoz appointed a...
Health Catalyst has appointed Tami Reller to its board of directors, effective October 1, 2026, where she will serve as audit chair and join the compensation committee. This move supports the company's next growth phase under new CEO Simeon Kohl, foc...
